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TMEPAI ⁄ PMEPA1 is a transmembrane protein that was originally identified as a
prostatic RNA, the synthesis of which is induced by testosterone or its deriva-
tives. We have recently identified TMEPAI as a direct target gene of transforming
growth factor-b (TGF-b) ⁄ Smad signaling that participates in negative feedback
control of the duration and intensity of TGF-b ⁄ Smad signaling. TMEPAI is consti-
tutively and highly expressed in many types of cancer and is associated with
poor prognosis. Here, we report that TMEPAI is highly expressed in the lung ade-
nocarcinoma cell lines Calu3, NCI-H23, and RERF-LC-KJ. Expression of TMEPAI in
these cancer cells was significantly suppressed by a TGF-b receptor kinase antago-
nist, SB208, and by TGF-b neutralizing antibodies. These results suggest that con-
stitutive expression of TMEPAI in these cancer cells depends on autocrine TGF-b
stimulation. Knockdown of TMEPAI in Calu3 and NCI-H23 cells enhanced levels of
Smad2 phosphorylation and significantly suppressed cell proliferation in the pres-
ence of TGF-b, indicating that highly expressed TMEPAI suppresses levels of Smad
phosphorylation in these cancer cells and reduces the growth inhibitory effects
of TGF-b ⁄ Smad signaling. Furthermore, knockdown of TMEPAI in Calu3 and NCI-
H23 cells suppressed sphere formation in vitro and tumor formation in s.c. tissues
and in lungs after tail vein injection in NOD-SCID mice in vivo. Together, these
experiments indicate that TMEPAI promotes tumorigenic activities in lung cancer
cells.
T he transforming growth factor-b (TGF-b) family com-prises 33 multifunctional polypeptide factors that include
TGF-bs, bone morphogenetic proteins, growth ⁄differentiation
factors, inhibin, and activins.(1,2) Transforming growth factor-b
signaling has essential effects on a wide variety of cellular
activities, such as cell cycle control, cell adhesion, differentia-
tion, ECM formation, apoptosis, angiogenesis, immune
functions, and cancer progression.(2–6) Transforming growth
factor-b signaling is initiated by ligand-induced heteromeric
complex formation of the specific type I and type II serine
⁄ threonine kinase receptors. Transforming growth factor-b type
I receptor (TbRI), also termed activin receptor-like kinase-5, is
phosphorylated and activated by TGF-b type II receptor
(TbRII). Activated TbRI catalyzes the C-terminal serine phos-
phorylation of receptor-regulated Smads (Smad2 and Smad3),
and the activated receptor-regulated Smads form a ternary
complex with the common mediator Smad (Smad4). The acti-
vated Smad complexes then translocate into the nucleus, where
they regulate the transcription of specific target genes together
with other transcription factors and cofactors.(7–10)
Transmembrane prostate androgen-induced RNA (TME-
PAI), alternatively termed PMEPA1, STAG1, ERG1.2, or
N4wbp4, was originally identified as a prostatic RNA, the
synthesis of which is induced by testosterone or its
derivatives.(11) In addition to androgen, epidermal growth
factor (EGF), activation of the RAS ⁄ERK pathway,
mutant p53, and TGF-b have been reported to induce
TMEPAI.(12–16) We have recently reported that TMEPAI is a
direct target gene of TGF-b ⁄Smad signaling, which requires
Smad3, Smad4, and TCF7L2 as cobinding transcription fac-
tors.(17) TMEPAI is a transmembrane protein containing two
PY motifs that can interact with HECT-type E3 ubiquitin
ligases.(18) TMEPAI has also been reported to mediate
growth inhibition and p53-inducible apoptosis.(13,18) We have
shown that TMEPAI can interact with Smad2 and Smad3 by
way of its Smad interaction motif (SIM) to sequester Smads
from TGF-b ⁄Smad signaling. Because of the competition
with SARA for binding to Smads, TMEPAI participates in
negative feedback regulation of the duration and intensity of
TGF-b ⁄Smad signaling.(19)
High levels of TMEPAI expression have been reported in
renal cell carcinoma, colon cancer, breast cancer, and ovarian
cancer as well as in several cancer cell lines.(12,14,20) Genome-
wide studies, which compared the gene expression levels of
invasive cancer tissues with normal counterpart tissues or prein-
vasive cancers, suggested that TMEPAI is one of the most highly
inducible genes in invasive cancers.(21,22) TMEPAI was further
suggested as a “molecular switch” that converts TGF-b signaling
from a tumor suppressor to a tumor promoter.(23) These lines of
evidence suggest an oncogenic function of TMEPAI in many
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cancers. However, how TMEPAI regulates tumor progression
remains largely unknown. In this study, we aimed to investigate
the tumorigenic activities of TMEPAI in lung cancer cell lines.
Materials and Methods
Monoclonal antibody. We constructed a 117-bp DNA frag-
ment coding a C-terminal peptide (249–287) of human TME-
PAI isoform a, which is conjugated with a GST gene to
produce a recombinant GST-TMEPAI (249–287) fusion pro-
tein for immunization (Fig. S1). TMEPAI-knockout mice were
peritoneally immunized once a week for 3 weeks with purified
GST-TMEPAI (249–287) mixed in Freund’s adjuvant. Hybrid-
oma cells were established and cloned essentially according to
the methods described elsewhere.(24,25) The established clones
were examined by ELISA, immunoblot analysis, immunopre-
cipitation, and immunofluorescence. Monoclonal antibodies
from clone 9F10 were used for examination of lung cancer
cells after large-scale preparation in nude mice ascites and
purification using Protein-G columns.
Plasmid construction. The expression plasmid for human
TMEPAI ⁄V5 was previously described.(19) C18ORF1 cDNA
was obtained by RT-PCR. The PCR product was inserted into
the pcDNA3.1 ⁄V5 vector (Invitrogen, Carlsbad, CA, USA).
Both TMEPAI and C18ORF1 constructs were connected to the
V5-epitope tag at their C-terminus. All plasmids were
sequenced before use.
Cell culture. HaCaT cells (spontaneously immortalized human
keratinocyte cell line) and COS7 cells (African green monkey
kidney cells transformed by SV40) were cultured in DMEM
(Sigma) containing 10% FCS (Biowest, Rosenberg, TX, USA)
and nonessential amino acids (Invitrogen). NCI-H23 and RERF-
LC-KJ cells were cultured in RPMI-1640 medium containing
10% FCS. Calu3 cells and HepG2 cells were cultured in mini-
mum essential medium (Sigma) containing 10% FCS. Non-tar-
geting shRNA (SHC002), TMEPAI shRNA#9 (CCG GGA GCA
AAG AGA AGG ATA AAC ACT CGA GTG TTT ATC CTT
CTC TTT GCT CTT TTT), and TMEPAI shRNA#10 (CCG
GGA GTT TGT TCA GAT CAT CAT CCT CGA GGA TGA
TGA TCT GAA CAA ACT CTT TTT) ligated in a pSUPER
RNAi system (Oligoengine, Seattle, WA, USA) were used for
knockdown of TMEPAI. For the selection of stable TMEPAI-
knockdown clones, Calu3 or NCI-H23 cells were cultured in the
presence of 0.6 lg ⁄mL or 1 lg ⁄mL puromycin (Sigma), respec-
tively. The TGF-b receptor kinase inhibitor SD208 (Tocris
Bioscience, Bristol, UK) and anti-TGF-b neutralizing antibody
(R&D Systems, Minneapolis, MI, USA) were used to block
TGF-b signaling.
Luciferase assay. HepG2 cells were transfected with
(CAGA)12-luc using FuGENE6 (Roche, Penzberg, Germany),
treated with TGF-b or 50% v ⁄v of heat-treated serum-free con-
ditioned media (80°C, 10 min) after 24 h of incubation with
HaCaT or lung cancer cell lines. Luciferase activities were
determined by Luciferase Assay Systems (Promega, Madison,
WI, USA) and normalized to b-galactosidase activity of co-
transfected CH110 (GE Healthcare, Piscataway, NJ, USA).
Immunoblot analysis and immunoprecipitation. To examine
the sensitivity and specificity of the established antibodies in
immunoblot analysis and immunoprecipitation, the TMEPAI
⁄V5 or C18ORF1 ⁄V5 expression plasmids were transfected into
COS7 cells (5 9 106 cells ⁄6-cm dish) using FuGENE 6 (Roche
Applied Science). Thirty-six hours after the transfection, the
cells were dissolved in 500 lL TNE buffer and the debris was
removed by centrifugation as previously described.(19) For
immunoprecipitation, the lysate was precleared with protein
G-Sepharose beads (GE Healthcare) for 30 min at 4°C with
end-over-end rotation and then incubated with anti-V5 antibody
(Sigma) or anti-TMEPAI antibodies for 2 h at 4°C. The immune
complexes were precipitated by incubation with protein G-
Sepharose beads for 30 min at 4°C followed by three washes
with TNE buffer. The immunoprecipitated proteins and aliquots
of the total cell lysate were separated by SDS-PAGE, and trans-
ferred to Hybond-C Extra membranes (GE Healthcare). The
membranes were probed with different primary antibodies and
then incubated with HRP-conjugated secondary antibodies and
chemiluminescent substrate solution (Thermo Scientific, Wal-
tham, MA, USA). Endogenously expressed TMEPAI in HaCaT
or lung cancer cell lines was also detected by immunoblot analy-
sis using total cell lysates with ⁄without TGF-b stimulation.
Immunofluorescence staining. HaCaT and NCI-H23 cells were
cultured on glass coverslips, fixed with 4% paraformaldehyde-
PBS, permeabilized with 0.3% Triton X-100 ⁄PBS, and
incubated with 1% BSA. Cells were then incubated with anti-
TMEPAI 9F10 antibody and then with Alexa 488-labeled goat
anti-mouse IgG (Molecular Probes, Eugene, OR, USA). The
nuclei were stained with Hoechst 33342 (Sigma). Intracellular
localization was then observed by fluorescence microscopy (Ax-
iovert 200; Zeiss, Oberkochen, Germany).
Cell proliferation assay. Cells were seeded in 24-well plates,
cultured for the indicated time periods, and counted with a
hemocytometer.
Sphere formation assay. Spheres were cultured in DMEM
⁄F12 serum-free medium (Invitrogen) supplemented with B27
(Invitrogen), 20 ng ⁄mL EGF (Sigma), and 20 ng ⁄mL basic
fibroblast growth factor (R&D Systems) in an ultra-low attach-
ment culture dish (Corning, NY, USA).
In vivo tumor formation assay. For cancer cell implantation,
107 cells were s.c. injected into 8-week-old female NOD-SCID
mice. After 3 months, the mice were killed and the tumors
weighed. All animal experiments were approved by the animal
experiment committee of the University of Tsukuba (Tsukuba,
Japan) and carried out in accordance with the university’s
animal experiment guidelines and the provisions of the
Declaration of Helsinki in 1995.
In vivo lung metastasis assay. A suspension containing 106
cells in 0.2 mL PBS was injected into the lateral tail vein of
7-week-old NOD-SCID mice. After 8 weeks, the animals were
killed and the removed lungs were fixed in 10% neutralized
formalin solution, embedded in paraffin, sliced into 3-lm sec-
tions, and stained with H&E or immunostained with Ki-67
antibody (Novocastra, Newcastle Upon Tyne, UK). Three ani-
mals were used in each group. The tumor areas in a represen-
tative cut surface were measured with an Olympus Virtual
Slide System and with ASW morphometry software (Olympus,
Tokyo, Japan).
Statistical analysis. Statistical analyses of the data were
carried out using a statics function in Microsoft Office (Micro-
soft, Redmond, WA, USA) and the t-test. Probability values of
<0.05 were considered significant.
Results
Establishment and characterization of mAbs for TMEPAI. To
investigate the pathophysiological functions of TMEPAI, we
first generated mAbs for TMEPAI. Antibody titers were
checked by ELISA in the sample sera after each immunization.
Consequently, the immunized mice with conspicuous increase
of anti-TMEPAI activity in the sera were used for hybridoma
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formation. After several screenings, we obtained six clones
(4E5, 4C10, 4D11, 9F10, 1C4, and 6C7), which provided sen-
sitive and specific detection of GST-TMEPAI in the first series
of ELISA screening. The mAbs from these six clones were
then prepared on a large scale and purified, and the isotypes of
these antibodies were determined. The isotype of four of the
clones (4E5, 4C10, 9F10, and 6C7) was IgG1, that of 4D11
was IgG2a, and that of 1C4 was IgG2b. All of the antibodies
contained the kappa light chain except for 6C7, which con-
tained the lambda light chain. Next, we examined the sensitiv-
ity of these antibodies by ELISA again. Four purified
antibodies, 4E5, 4C10, 9F10, and 6C7, showed efficient and
specific activity in the ELISA for TMEPAI at 0.4 lg ⁄mL anti-
body concentration (Fig. S2a). We next used the antibodies for
immunoblot analysis using COS7 cell lysates transfected with
TMEPAI ⁄V5 or C18ORF1 ⁄V5 expression plasmids. Four
monoclonal antibodies, 4E5, 4C10, 9F10, and 6C7, specifically
recognized only TMEPAI, and three of them, 4E5, 4C10, and
9F10, could also efficiently work for the immunoprecipitation
assay (Fig. S2b). Moreover, we characterized the ability of
these TMEPAI antibodies in immunofluorescence staining. The
TMEPAI ⁄V5, C18ORF1 ⁄V5, or pcDNA3.1-alone vector was
transfected into 911 cells, and the subcellular localization of
TMEPAI was detected at 24 h after transfection. Consistent
with the previous finding of TMEPAI localization in early
endosomes, anti-TMEPAI immunofluorescence gave cytoplas-
mic dot patterns. Three of the examined antibodies, 4E5,
9F10, and 6C7, specifically recognized TMEPAI and did not
cross-react with C18ORF1 (Fig. S2c).
Enhanced and constitutive expression of TMEPAI in lung cancer
cell lines. Using anti-TMEPAI (9F10) antibody, we evaluated
TMEPAI expression levels in the human lung adenocarcinoma
cell lines Calu3, NCI-H23, and RERF-LC-KJ. HaCaT cells
were used as a positive control. HaCaT cells expressed detect-
able levels of TMEPAI only in the presence of more than 8 h
of TGF-b stimulation; there were no detectable levels of TME-
PAI without TGF-b stimulation (Fig. 1a). In contrast, all three
of the examined lung cancer cell lines expressed detectable
levels of TMEPAI even in the absence of TGF-b stimulation.
Notably, Calu3 constitutively expressed high levels of TME-
PAI, whereas NCI-H23 and RERF-LC-KJ expressed distinct
but relatively low levels of TMEPAI and enhanced TMEPAI
expression approximately twofold in response to TGF-b
(Fig. 1b). Endogenous TMEPAI could also be detected as
(a)
(c)
(b)
Fig. 1. Enhanced expression of TMEPAI in lung
cancer cells. (a) Induction of TMEPAI by 5 ng ⁄ mL
transforming growth factor-b (TGF-b) in HaCaT
cells. Endogenous TMEPAI was detected by a
monoclonal anti-TMEPAI antibody (9F10). b-actin
was used as the loading control. Relative amounts
of TMEPAI (TMEPAI ⁄ b-actin) were measured by NIH
Image and are shown below the panel.
(b) Expression of TMEPAI in the lung cancer cell
lines Calu3, RERF-LC-KJ, and NCI-H23 detected as in
(a). (c) HaCaT or NCI-B23 cells were treated with
5 ng ⁄ mL TGF-b as indicated. After treatment, the
cells were subjected to fluorescence microscopy
using anti-TMEPAI antibody.
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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cytoplasmic dot patterns in HaCaT and NCI-H23 cells by
immunofluorescence staining (Fig. 1c).
Transforming growth factor-b signaling mediates enhanced
expression of TMEPAI in lung cancer cells. The high expression
levels of TMEPAI in lung cancer cells prompted us to examine
how TMEPAI expression is constitutively enhanced in these
cells. To investigate the possibility that TGF-b signaling is
involved in TMEPAI expression, cells were treated with the
TGF-b receptor kinase inhibitor SD208 or anti-TGF-b neutraliz-
ing antibodies. TMEPAI disappeared from all cell lines in the
presence of SD208 (Fig. 2a). Although the effects of the TGF-b
neutralizing antibodies were not complete, they did cause the
TMEPAI levels to significantly decrease to levels correlating
with Smad2 phosphorylation levels in all three cell lines
(Fig. 2b). We further examined TGF-b activities in the condi-
tioned media incubated 24 h with the lung cancer cells. Calu3
secreted abundant TGF-b in the culture media and it had posi-
tive correlation with the levels of TMEPAI expression (Fig. 2c).
Knockdown of TMEPAI enhances Smad phosphorylation and
growth inhibitory responses of TGF-b. We next engineered
stable knockdown of TMEPAI by two individual shR-
NAs (shTMEPAI#9 and shTMEPAI#10). These shRNAs
significantly reduced TMEPAI expression in Calu3 cells
(Calu3-sh#9 and Calu3-sh#10; Fig. 3a). As a result, phosphor-
ylated Smad2 levels were clearly enhanced (Fig. 3b).
Significantly stronger cell growth inhibition was obtained in
Calu3-sh#9 and Calu3-sh#10 cells in the presence of 0.1 ng
⁄mL TGF-b, and it was recovered by anti-TGF-b neutralizing
antibodies (Fig. 3c,d). Similar results were obtained with NCI-
H23 cells (Fig. S3a–c).
Sphere-forming activities enhanced by TMEPAI. We further
investigated the functional significance of TMEPAI in sphere-
forming activities. The sphere-forming activities of TMEPAI
knockdown cells were significantly reduced both in Calu3
(Fig. 4a,b) and in NCI-H23 cells (Fig. S3d,e).
In vivo tumor formation enhanced by TMEPAI. In addition, we
carried out xenograft assays in NOD-SCID mice. Calu3-sh#9
and Calu3-sh#10 cells were s.c. injected into NOD-SCID mice.
Three months after injection, the tumors were collected and
weighed. As shown in Figure 5, the tumors of the Calu3-sh#9
and Calu3-sh#10 cells were significantly smaller than those of
the control cells in NOD-SCID mice. The results of the
NCI-H23 cells were essentially the same (Fig. S4).
Metastatic tumor formation in lungs enhanced by TMEPAI. To
examine the effects of TMEPAI on the metastatic potential
in lungs, we injected Calu3-sh#9 and Calu3-sh#10 cells into
(a)
(b)
(c)
Fig. 2. Transforming growth factor-b (TGF-b)
signaling mediates the expression of TMEPAI in
lung cancer cell lines Calu3, NCI-H23, and RERF-
LC-KJ. (a) The TGF-b receptor kinase inhibitor SD208
(1 lM ⁄ mL) or (b) a TGF-b neutralizing antibody
(5 lg ⁄ mL) were added 1 h before stimulation with
5 ng ⁄ mL TGF-b for 8 h as indicated. The cell lysates
were then subjected to immunoblot analysis.
TMEPAI was detected by using anti-TMEPAI
antibody and the levels of phosphorylated Smad2
were detected with anti-phospho Smad2 antibody
(PS2). b-actin was used as the loading control.
(c) TGF-b activities in serum-free conditioned media
after 24 h of incubation with the indicated cells
were measured by (CAGA)12-luc reporter assay. The
means  SDs are shown.
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the tail veins of NOD-SCID mice. Eight weeks after injec-
tion, mice were killed and the collected lungs were examined
histopathologically with H&E staining. We also stained for
Ki-67 to detect proliferating cancer cells. Using morphomet-
ric software, we calculated the percentage of the representa-
tive tumor areas in the total lung areas. Calu3-sh#9 and
Calu3-sh#10 cells formed significantly smaller tumors both is
size and numbers than those of the control Calu3 cells
(Fig. 6). These results indicated that knockdown of TMEPAI
suppresses the ability of lung cancer cells to develop meta-
static tumors in lungs.
Discussion
Multiple positive and negative regulators have critical roles in
the regulation of the TGF-b ⁄Smad signaling pathway.(26,27)
(a)
(c)
(d)
(b)
Fig. 3. Calu3-shTMEPAI cells have increased
sensitivity to transforming growth factor-b (TGF-b).
(a) Generation of TMEPAI-knockdown Calu3 cell
lines. The expression of TMEPAI was significantly
suppressed by stable expression of two
independent shRNAs (#9 and #10) targeting
TMEPAI mRNA. Cells were treated with TGF-b for
8 h, and endogenous TMEPAI was detected by
immunoblot analysis. b-actin was used as the
loading control. (b) Cells were stimulated with TGF-
b (1 ng ⁄ mL) for 1 h and phosphorylated Smad2 was
detected with anti-phospho Smad2 antibody (PS2).
b-actin was used as the loading control. (c,d) Cell
proliferation assays. (c) TMEPAI-knockdown Calu3
cells (Calu3-sh#9 and Calu3-sh#10) were cultured in
12-well plates without TGF-b (left), with TGF-b
(0.1 ng ⁄ mL) (middle) or with TGF-b (0.1 ng ⁄ mL) and
TGF-b neutralizing antibody (1 ng ⁄ mL) (right), as
indicated. The cell numbers were counted every
second day. The means  SDs are shown. (d) Mean
percentage growth inhibition by TGF-b (0.1 ng ⁄ mL)
and the reversal by inclusion of TGF-b neutralizing
antibody (1 ng ⁄ mL) was calculated on day 9 in each
cell line. Calu3 sh. control, Calu3 sh. control
expresses non-targeting shRNA (SHC002, Sigma) in
pLKO.1-puro vector.
(a) (b)
Fig. 4. Calu3-shTMEPAI cells have decreased
sphere-forming activities. (a) Control and TMEPAI-
knockdown Calu3 cells (Calu3-sh#9 and Calu3-
sh#10) were cultured in sphere formation medium
for 12 days. Typical photographs are shown. (b) The
numbers of spheres larger than 100 lm in diameter
were counted. The means  SDs are shown.
*P < 0.01 (vs control). Calu3 sh. control, Calu3 sh.
control expresses non-targeting shRNA (SHC002,
Sigma) in pLKO.1-puro vector.
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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Disruption of the balance between these positive and negative
regulators can lead to various diseases.(28–30) We have recently
identified TMEPAI as a direct target gene of TGF-b signaling
that participates in negative feedback regulation of the duration
and intensity of TGF-b ⁄Smad signaling.(17,19) TMEPAI has a
family molecule, C18ORF1; we established several mAbs
specific for TMEPAI without cross-reactivity to C18ORF1.
Previous studies indicated that TMEPAI is highly expressed
in various cancers such as renal cell carcinoma, colon cancer,
breast cancer, and ovarian cancer.(12,14,20) Genome-wide stud-
ies, which compared the gene expression levels of invasive
cancer tissues with normal counterpart tissues or preinvasive
cancers, suggested that TMEPAI is one of the most highly
inducible genes in invasive cancers.(21,22) Furthermore, dysre-
gulation of TGF-b signaling was identified as an important
mediator of lung cancer invasion.(30) Therefore, we examined
the expression of TMEPAI in lung cancer cell lines. Both
immunoblot and immunofluorescent analyses clearly detected
(a) (b)
Fig. 5. Calu3-shTMEPAI cells have decreased
tumor-forming activities. (a) TMEPAI-knockdown
Calu3 cells (Calu3-sh#9 and Calu3-sh#10) were
injected s.c. into NOD-SCID mice with Matrigel
supplement. After 3 months, the tumors were
harvested and photographed. (b) The tumors were
weighed. The means  SDs are shown. *P < 0.01 (vs
control). Calu3 sh. control, Calu3 sh. control
expresses non-targeting shRNA (SHC002, Sigma) in
pLKO.1-puro vector.
(a)
(b)
(c) (d)
Fig. 6. Calu3-shTMEPAI cells have decreased
tumorigenic activity in the lungs. TMEPAI-
knockdown Calu3 cells (Calu3-sh#9 and Calu3-
sh#10) were injected into the tail vein of NOD-SCID
mice (106 cells in 200 lL PBS ⁄ mice). (a) After
8 weeks, the lungs were collected and
photographed. (b) The thin sections of lungs were
stained with H&E. Scale bar = 1 mm. Higher
magnifications show a typical metastatic area.
(c) The percentages of tumor areas were measured
by image analyses. The means  SDs are shown.
*P < 0.01 (vs control). (d) The same lung sections as
those in (b) were stained with anti-Ki67 antibodies.
The nuclei of proliferating cancer cells showed
positive staining. Scale bar = 100 lm. Calu3 sh.
control, Calu3 sh. control expresses non-targeting
shRNA (SHC002, Sigma) in pLKO.1-puro vector.
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high levels of TMEPAI expression in all three examined lung
cancer cell lines (Fig. 1b).
The mechanism of enhanced TMEPAI expression in cancer
cells is an important issue to be elucidated. Oncogenes can be
activated by gene amplification and other mechanisms. Human
chromosomal region 20q13, on which the TMEPAI gene is
located, is frequently amplified in breast cancers.(31,32) Expres-
sion of TMEPAI in lung cancer cells disappeared in the pres-
ence of a TGF-b receptor kinase inhibitor and was
significantly suppressed by anti-TGF-b neutralizing antibodies
(Fig. 2a,b). Although Calu3 cells expressed high levels of
TMEPAI in the absence of detectable Smad2 phosphorylation,
expression of TMEPAI was significantly suppressed by a
TGF-b receptor kinase inhibitor (Fig. 2a). Our previous find-
ings indicated that Smad3 and Smad4 are essential for the
TGF-b-inducible expression of TMEPAI.(17) However, it is
also known that the expression of TMEPAI is enhanced by
Wnt, EGFR ⁄Ras ⁄MAPK, androgen, and mutant p53 as shown
by us and others.(11–13,17,33) The effects of SD208 (Fig. 2a)
indicate that activity of type I TGF-b receptor kinase is
required for the stable expression of TMEPAI in lung adeno-
carcinoma cells. Many of these cells usually have activated
EGFR ⁄RAS ⁄MAPK signaling, even if Smad2 phosphorylation
is undetectable in immunoblot analysis. These results suggest
that cancer cells can maintain TMEPAI expression by multiple
oncogenic signaling to suppress Smad phosphorylation down
to undetectable levels but even in these cases TGF-b receptor
kinase activity is required to support TMEPAI expression. The
contributions of synergistic effects of multiple oncogenic sig-
naling, including the role of the TGF-b non-Smad signaling
pathway in cancer cells, must be elucidated in the future.
The functions of TMEPAI in cancer cells are the next
important issue to be examined. Recent reports indicated that
knockdown of TMEPAI suppresses the tumorigenic activities
of breast cancer cells and androgen receptor-negative prostatic
cancer cells.(23,34) Here, we showed that knockdown of TME-
PAI in lung cancer cells potentiates TGF-b-inducible Smad
phosphorylation and growth inhibitory responses to TGF-b
(Fig. 3). Consequently, the sphere-forming activity in vitro,
s.c. tumor formation, and lung metastasis were significantly
suppressed in NOD-SCID mice (Figs 4–6, S3, S4). Liu
et al.(34) reported that knockdown of PMEPA1 ⁄TMEPAI
suppresses the Smad3 ⁄4-cMyc-p21Cip1 pathway in androgen
receptor-negative prostatic cancer cells. These effects can be
explained by the suppressive function of TMEPAI on Smad
signaling through its SIM domain. However, Prajjal et al.(23)
identified suppression of Akt phosphorylation and expression
of hypoxia-inducible factor-1b and vascular endothelial growth
factor in TMEPAI-knockdown xenograft breast tumors. These
effects may be independent from the Smad regulatory function
of TMEPAI. Both TMEPAI and its family molecule C18ORF1
share tandem PY motifs interposing a SIM domain. The
possibility of another TMEPAI function such as that indicated
by Prajjal et al. may explain the reason for TMEPAI’s
involvement among multiple regulators of Smad signaling in
outstandingly divergent cancers. Further studies will be
required to reveal the overall functions of TMEPAI in cancer
development.
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